Program
KAT6 Inhibitor OP-3136
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Olema Pharmaceuticals.
Furthest: phase 1, since Jan 14, 20251 company-led study, 1 open or runningNext primary completion: May 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Olema Pharmaceuticals | 11 open or running | phase 1since Jan 14, 2025 | Jan 14, 2025 | May 30, 2027phase 1 · NCT06784193 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 14, 2025First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06784193 · 180 planned · United States, Australia, France and more
Ahead
- May 30, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06784193
TargetBeta
“An orally bioavailable inhibitor of histone acetyltransferases KAT6A (MOZ; MYST3) and KAT6B (MORF; MOZ2; MYST4), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| prifetrastat | Pfizer | phase 3 | 10 |
| KAT6A/B Inhibitor BG-75202rule | BeOne Medicines | phase 1 | 2 |
| HRS-2189 | Jiangsu HengRui Medicine | phase 1 | 2 |
| KAT6/KAT7 Inhibitor PF-08032562rule | Pfizer | phase 1 | 1 |
| KAT6/KAT7 Inhibitor IDE574rule | ideaya-biosciences | phase 1 | 1 |
| HLX97 | Fosun Pharma | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06784193Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 1 | Recruiting | May 30, 2027 | 180 |
How it is read
Names in the registry
- “OP-3136”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.